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Endemic Burkitt lymphoma (BL), a highly aggressive lymphoma, is the most common childhood 
cancer in sub-Saharan Africa. The age standardised rate is 3.3 in the sub-Saharan region and 2.6 in 
the north-west region of Cameroon.1,2
Limited resources, such as unaffordable or unavailable drugs and limited supportive care, have 
led to the development of treatment with high frequency cyclophosphamide (CPM) during 
induction therapy. A 61% one-year disease-free survival rate was recorded in Cameroon with this 
treatment protocol, compared to survival rates of ≥ 80% in developed countries.3,4,5
Families in north-west and south-west Cameroon are mainly poor subsistence farmers and often 
live far away from the treatment centre. Guardians have to stay in hospital with the patient, 
provide meals for their child and pay the hospital bills. In this study free treatment was provided.
Malnutrition (weight for age < 5th centile) was present in 50% of patients with BL in Malawi and 
in 30% of patients with BL in Cameroon on admission.3.6 Tolerance for chemotherapy and survival 
Background: Malnutrition is common in children diagnosed with cancer in Africa, and it adds 
to the morbidity and mortality of treatment. Nutritional support is known to reduce morbidity 
and mortality of treatment.
Aim: The aim of this study was to record changes in anthropometric parameters, morbidity 
and mortality in patients admitted with Burkitt lymphoma (BL) whose diet was supplemented 
with protein, vitamins and minerals during induction chemotherapy.
Methods: Seventy consecutive newly diagnosed BL patients were enrolled. The diet was 
supplemented with a daily egg, 200 mL F-75 formula and vitamins. Guardians received 3 cups 
of dry rice and $1 daily to buy and prepare meals for the patient and themselves whilst in the 
hospital. Height, weight, triceps skinfold (TSF) and mid-upper arm circumference (MUAC) 
were recorded on days 1 and 28. Co-morbidities at diagnosis were treated, and neutropenia 
and febrile episodes managed with a standard protocol. Two patients who died within 24 h 
after admission were excluded from the anthropometric analyses.
Results: The mean age was 8 (range 2–16) years and the male:female ratio was 42:28. The St 
Jude stage distribution was as follows: Stage I = 6%, II = 4%, III = 69%, IV = 21%. Weight for 
age was < 10th centile at diagnosis in 18% (but influenced by tumour mass). Weight was 
unchanged or increased by ≥ 5% in 66% of patients on Day 28. The TSF was < 3rd centile in 47% 
of patients and increased by ≥ 0.5 cm in 57%. The MUAC was < 3rd centile in 16% of patients 
at diagnosis and in 10% of patients on Day 28. Febrile episodes in 60% and neutropenia in 18% 
of patients were successfully treated. Two patients died from presumed renal failure. The 
overall death rate (including the two deaths within 24 h after admission before chemotherapy 
was started) was 5.5% (n = 4).
Conclusion: The TSF improved in the majority and the MUAC improved in some patients. 
Febrile neutropenia and febrile episodes could be successfully managed. The death rate during 
induction was lower than in our previously published results with the same chemotherapy 
protocol. Dietary supplementation should be a standard component of treatment in paediatric 
patients with cancer.
Burkitt lymphoma – Nutritional support during 
induction treatment: Effect on anthropometric 
parameters and morbidity of treatment
Copyright: © 2018. The Authors. Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License.
Page 2 of 5 Original Research
http://www.sajo.org.za Open Access
rates are influenced by the nutritional status.7,8,9,10 Malnutrition 
is associated with a higher rate of neutropenia and serious 
infections, treatment delays, reduced chemotherapy tolerance 
and a poorer outcome.8 The impact of nutritional status on 
outcomes in children with cancer is an important but 
neglected area of research.11 Prevention of early deaths 
during the induction phase of treatment is important to 
improve the overall survival rate.
The majority (85%) of BL patients have advanced disease and 
a large abdominal facial tumour burden, and they may eat 
and drink poorly during the first 3 days of treatment.3,6
Weight for age (W/A) is an inaccurate parameter of nutrition 
in the acute setting. Weight for height (W/H) is a better 
parameter of nutrition but may be influenced by factors such 
as tumour mass, oedema and ascites on admission in children 
with large tumours. The triceps skinfold (TSF), an indicator 
of body fat, and the mid-upper arm circumference (MUAC), 
an indicator of lean body mass, correlate with the golden 
standard of body composition, the DEXA scan, and are more 
appropriate objective measurements of nutrition.11,12,13 The 
5th centile for TSF in patients aged 4 to 14 years ranges from 
5 mm to 6 mm in boys and from 6 mm to 8 mm in girls. The 
5th centile for MUAC ranges from 126 mm to 172 mm in boys 
and 115 mm to 174 mm in girls.14
The objective of this descriptive prospective study was to 
document the anthropometric parameters and co-morbidities 
in newly diagnosed BL patients, to record morbidity of 
treatment and to measure the changes in anthropometric 
parameters during the 28-day induction treatment period 
in patients who received a standardised treatment protocol 
and a daily dietary supplement of protein, minerals and 
vitamins.
Methods
The study was supervised by a resident paediatrician (MT). 
Seventy-two consecutive patients were admitted with BL 
between April 2010 and March 2011 to the Banso, Mbingo and 
Mutengene Baptist Hospitals in the north-west and south-
west regions of Cameroon. Two patients who died of advanced 
disease within 24 h of admission were excluded from 
anthropometric analysis. Standard diagnostic procedures 
on admission included fine needle aspiration (FNA), an 
abdominal ultrasound (US) with measurement of the largest 
intra-abdominal mass, bone marrow aspiration (BM), 
cerebrospinal fluid (CSF) cytology, a full blood count (FBC), 
malaria smear, sickle cell test, human immunodeficiency 
virus (HIV) screening test, urinalysis and microscopy of 
faeces. The FBC was repeated before every chemotherapy 
pulse on days 8 and 14 and when fever occurred. The St Jude 
staging system was used.15
All patients were treated with the 2008 Cameroon BL 
protocol. Induction therapy commenced with 48 h of 
parenteral hydration at 3L/M2 and oral allopurinol to prevent 
tumour lysis. A metoclopramide tablet was given 2 h before 
and 4 h after chemotherapy to prevent vomiting. Furosemide 
was used when needed to achieve a target urinary output of 
≥ 3 mL/kg/h during the first 48 h. Chemotherapy was started 
24 h after the onset of hydration and consisted of 40 mg/kg 
CPM (oral or intravenous), 12.5 mg intrathecal methotrexate 
and 12.5 mg intrathecal hydrocortisone on days 1, 8 and 15. 
The response to treatment was assessed on Day 28 by clinical 
assessment and abdominal US prior to starting maintenance 
chemotherapy. The response to and outcome of treatment 
will not be discussed in this article.
Every patient received a boiled egg, 200 mL of World Health 
Organization (WHO) F-75 formula and a multivitamin tablet 
as inpatients every day during the first 14 days, and guardians 
were provided with eggs and multivitamin tablets on 
discharge to be given daily at home until the follow-up visit 
on Day 28. Guardians, who have to stay with the patient in 
the ward, received a daily ration of three cups of dry rice and 
$1 in cash to buy and prepare local food for their child and 
themselves. Parenteral nutrition was not available. Parents in 
general strongly object to nasogastric tube feeding, and this 
was rarely used.
Anthropometric observations included measurement of 
weight (W) in kg and height (H), MUAC and TSF in cm, with 
a standardised scale, Harpenden calliper and a United 
Nations Children’s Fund (UNICEF) measuring tape on days 
1 and 28. Nurses were trained to perform these measurements. 
Two successive measurements were performed and the 
average value was recorded. Percentiles of W/A, H/A and 
body mass index (BMI) were determined with WHO 
Anthroplus software. Weight-for-age percentiles were only 
determined in children ≤ 10 years because WHO standards 
above age 10 years are not available.14,15
Coexisting diseases such as malaria and urinary or intestinal 
parasites were treated. A blood transfusion was considered 
when the haemoglobin dropped ≤ 7 g/dl. Neutropenia was 
defined as a total white blood cell count of ≤ 1.0 × 109/L. Fever 
was defined as a single episode of a temperature of ≥ 38.5°C or 
two episodes ≥ 38°C within a 24-hour period. A malaria smear 
was performed immediately, and treatment was given if 
found positive. If negative, first-line antibiotic treatment 
with intravenous gentamicin and ampicillin was started 
immediately irrespective of the white cell count. Blood 
cultures were not available. A cephalosporin was added if 
fever persisted > 48 h. Mucositis was treated with oral nystatin 
and acyclovir. The full cost of treatment, including 
hospitalisation, investigations, all medicines and transport for 
follow-up visits, was provided at no cost to the guardians.
The treatment protocol was approved by the Institutional 
Review Board of the Cameroon Baptist Convention and 
parents gave informed signed consent.
Results
The 70 study patients included 42 boys and 28 girls with a 
mean age of 8 (range 2 to 16) years. Burkitt lymphoma was 
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confirmed on FNA in 76% and in the remainder on BM, CSF, 
abdominal US and clinical presentation. A marked reduction 
in tumour volume within 48 h was accepted as confirmation 
of the diagnosis in patients with a clinical diagnosis. The St 
Jude stage distribution was as follows: Stage I = 4 (6%), Stage 
II = 3 (4%), Stage III = 48 (69%) and Stage IV = 15 (21%). The 
US volume of the largest single abdominal mass (there 
usually are multiple masses) was > 400 mL in 32% of patients 
and < 400 mL in 49% of patients. The volume of the largest 
abdominal mass recorded exceeded 3000 mL. Abdominal US 
indicated ascites in two patients and a small pleural effusion 
in one patient.
On admission H/A was less than the 10th centile in 28 
(42%), W/A less than the 10th centile in 12 (18%), and BMI 
less than the 10th centile in 50% of patients aged > 10 years. 
The TSF was less than the 3rd WHO centile in 46%, and the 
MUAC less than the 3rd WHO centile in 16% of patients.16 
On Day 28 the TSF had increased by 0.5 cm in 69%, and the 
MUAC was now less than or equal to the 3rd centile in 10% 
of patients (Table 1). Weight loss of ≥ 5% of body weight 
was recorded in 42% of patients, and weight gain in 24% of 
patients. Fifty per cent of patients, with a largest recorded 
single abdominal tumour of < 400 mL in volume, gained 
weight during induction therapy. Five of seven patients 
without abdominal masses (St Jude Stages I and II) gained 
> 1 kg in weight, and six of these patients had an increase 
in TSF of > 5 mm. Anthropometric data are summarised 
in Table 1, and individual patients’ changes in TSF and 
MUAC are illustrated in Figure 1. Weight and height were 
not recorded in two and four patients, respectively, on 
admission, and height on Day 28 was not recorded in 11 
patients.
Two patients (3%) died from presumed tumour lysis and 
renal failure shortly after the first course of chemotherapy. 
Co-morbidities at diagnosis included malaria, sickle cell trait, 
intestinal parasites, schistosomiasis and HIV sero-positivity 
and are listed in Table 2. Three patients developed renal 
failure after the first dose of chemotherapy, of whom 
two died within the first week. Neutropenia occurred in 
12 (18%), febrile episodes in 42 (60%) and prolonged fever 
in 17 (24%) of patients. Fourteen patients (20%) received a 
blood transfusion. Other complications observed were 
diarrhoea and vomiting, mucositis, cough, dental problems, 
wound infection, chickenpox, skin infection and anal prolapse 
(which corrected spontaneously) (see Table 3). No other deaths 
occurred during the 28-day induction treatment period.
The limitations of this study, such as the unavailability of 
microbiological cultures, an intensive care unit, renal dialysis 
and parenteral feeding, were a result of the limited resources 
that were available in this setting at the time. We did not 
record the type and quantity of food that the parents gave to 








































MUAC, mid-upper arm circumference; TSF, triceps skinfold.
FIGURE 1: Changes in triceps skinfold and mid-upper arm circumference.
TABLE 1: Anthropometric parameters on days 1 and 28.
Parameters Day 1 (%) Day 28 (%)
Weight for age < 10th centile 18 -
Weight gain ≥ 5% - 21
Weight loss ≥ 5% - 34
Weight unchanged - 45
Height for age < 10th centile 42 -
Body mass index < 10th centile 50 -
MUAC < 3rd centile 16 10
TSF increase > 0.5 cm - 57
TSF < 3rd centile 47 -
MUAC, mid-upper arm circumference; TSF, triceps skinfold.
TABLE 2: Co-morbidities on admission in 70 patients.
Co-morbidity Number Percentage
Malaria 6 9
Sickle cell trait 5 7 
Intestinal parasites 7 10
Schistosomiasis 1 1
HIV seropositive 2 2
HIV, human immunodeficiency virus.
TABLE 3: Morbidity during treatment.
Event Number Percentage
Febrile episode 42 60
Fever > 48 h 17 24
Neutropenia 12 18
Diarrhoea, vomiting, gastroenteritis 9 13
Blood transfusion 14 20
Mucositis 4 6
Cough 2 3
Dental problems 2 3
Varicella 1 1
Skin infection 1 1
Wound infection 2 3
Anal prolapse 1 1
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Discussion
The H/A was less than the 10th centile in 42% and the W/A 
less than the 10th centile in 18% of patients. This confirms the 
high prevalence of poor nutrition in patients with BL at 
diagnosis. However weight reflects the short-term nutritional 
status at diagnosis and is overestimated in patients who have 
a large total tumour mass at diagnosis. Weight gain by Day 
28 was recorded in 21% of all the patients but in 71% (5/7) of 
patients who had no abdominal masses (Stage I and II 
disease) and in 50% of children who presented with smaller 
abdominal tumours. Co-morbidities such as malaria and 
intestinal parasites, which may adversely affect the nutritional 
state, were identified and fully treated on admission.
The egg, 200 mL of F75 and multivitamin tablet, which 
provided a minimum daily intake of 8 g of good quality 
protein and additional vitamins, minerals and trace elements, 
was supplemented by the food (mainly rice, maize, vegetables 
and fruit) that the parents prepared.
An increase of the TSF in 57% of patients, and a reduction in 
the number of children with a MUAC less than the third 
centile from 16% to 10%, indicates that the nutritional 
support had a positive effect. Fever, febrile episodes and 
co-morbidities were managed without serious consequences. 
Laboratory facilities were too limited to accurately quantify 
renal function.
There were two deaths during induction treatment, 
constituting a 2.8% death rate during treatment. If the two 
patients who died before chemotherapy was commenced are 
added, the overall death rate was 5.5% (4/72). No patients 
abandoned treatment. This death rate is significantly lower 
(P = 0.009, p < 0.5) than the 8.5% (24/129) rate recorded in a 
cohort of patients who had previously been treated with the 
same chemotherapy protocol at the same hospitals, but for 
whom the nutritional support provided was limited.3 The 
French–African Paediatric Oncology Group reported a 5.1% 
death rate with CPM induction treatment in 178 patients, but 
their exclusion of 79 patients from the analysis for unspecified 
reasons does not allow for a fair comparison.17 In a recent 
Malawian study, doxorubicin was added to CPM during 
induction, and a 12% death rate was reported during the first 
28 days. Ten of the seventy-eight Malawian patients, however, 
died before treatment was instituted and were not included 
as early deaths.18 All episodes of neutropenia and fever were 
successfully treated. The two deaths from renal failure may 
have been prevented if renal dialysis had been available.
We could find no publications on the changes in nutritional 
status and the effect of dietary support during the first month 
of treatment in children with endemic BL with which to 
compare our findings.
Although supplements of protein, vitamins and trace elements 
were provided, we did not record the type and quantity 
of food that the parents prepared and gave to their children. 
We intend to provide an optimal diet to our patients in the 
future and to educate parents how best to prepare available 
and affordable local food with the help of trained dieticians.
Conclusion
We have demonstrated that good enteral nutritional support 
during induction chemotherapy in a malnourished population 
of patients with BL resulted in an improvement in nutritional 
parameters in the majority of patients and was associated 
with a low morbidity and death rate during induction 
treatment. Nutritional support should be a standard 
component of treatment in all children with cancer.
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